Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444909 | 0.77 | MAPT (0.38) | MEN1KMT2ACASP1HSD17B10ALDH1A1 | |
| SCHEMBL8597444 | 0.72 | HRH4 (0.39) | — | |
| SCHEMBL2403993 | 0.67 | ALDH1A1 (0.33) | MEN1KMT2ACASP1HSD17B10GAA | |
| SCHEMBL7081619 | 0.66 | CES2 (0.31) | — | |
| SCHEMBL29031416 | 0.65 | NPC1 (0.41) | MEN1KMT2ACASP1HSD17B10GAA | |
| SCHEMBL11555181 | 0.65 | CES1 (0.31) | — | |
| SCHEMBL10965303 | 0.62 | — | — | |
| SCHEMBL940449 | 0.61 | ALDH1A1 (0.39) | MEN1KMT2ACASP1HSD17B10GAA | |
| SCHEMBL8534521 | 0.61 | CASP1 (0.43) | MEN1KMT2ACASP1HSD17B10GAA | |
| SCHEMBL6783904 | 0.60 | CDC25B (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| EP-1713804-B1 | CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1720870-B1 | HETEROCYCLICALLY SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
| CN-1910182-A | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1910182-A | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2007-02-07 | — | — | CN | disclosed |
| EP-1720870-A1 | HETEROCYCLICALLY SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| EP-1713804-A1 | CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| WO-2005073230-A1 | HETEROCYCLICALLY SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073231-A1 | CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | SLC5A2, SLC5A1, SLC2A2 | MEN1 2746/4885KMT2A 2936/4885CASP1 1743/4885 |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SLC5A2, QPCT, GLS | MEN1 3823/4885KMT2A 3783/4885CASP1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.